Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 2/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.33 |
| ▸ | F12 | P00748 | 2/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31133463 | 0.78 | WNT3A (0.33) | WNT3ATNKS2F12TNKSHTR2A | |
| SCHEMBL20897927 | 0.78 | WNT3A (0.33) | WNT3ATNKS2F12TNKSHTR2A | |
| SCHEMBL24656368 | 0.77 | WNT3A (0.32) | WNT3ATNKS2TNKS | |
| SCHEMBL31133375 | 0.75 | HSD11B1 (0.36) | WNT3ATNKS2TNKS | |
| SCHEMBL21818659 | 0.75 | HSD11B1 (0.36) | WNT3ATNKS2TNKS | |
| SCHEMBL795850 | 0.74 | GRM4 (0.40) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL795349 | 0.74 | NOS3 (0.44) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL21818641 | 0.73 | KDM4E (0.38) | WNT3ATNKS2TNKS | |
| SCHEMBL31133332 | 0.73 | KDM4E (0.38) | WNT3ATNKS2TNKS | |
| SCHEMBL24283716 | 0.72 | NOS3 (0.42) | CCR1CCR5CCR8NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | WNT3A 3874/4885TNKS2 3411/4885F12 510/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | WNT3A 3874/4885TNKS2 3411/4885F12 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.